

**LISTING OF CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-12 (Canceled)

Claim 13 (Currently amended): A method of detecting a colon cancer cancerous cell, selected from the group consisting of a brain cancer, prostate cancer, breast cancer, skin cancer, lymphoma, sarcoma, colon cancer, leukemia, ovarian cancer, and pancreatic cancer cell, expressing an epidermal growth factor repeat-like 6 (EGFL6) polypeptide in a biological sample, comprising

a) contacting the sample with an antibody or antigen binding fragment thereof that specifically binds to the polypeptide of SEQ ID NO: 24 ~~or a fragment thereof~~ for a time period sufficient to form a complex; and

b) detecting the complex, so that if a complex is detected it indicates the presence of the cancerous cell.

Claim 14 (Previously amended): The method of claim 13, wherein the EGFL6 polypeptide is selected from the group consisting of SEQ ID NO: 24, the amino acids 22 to 553 of SEQ ID NO: 24, and amino acids 412-426 of SEQ ID NO: 24.

Claim 15 (Canceled)

Claim 16 (Original): The method of claim 13, wherein the antibody is conjugated to a radioisotope, affinity label, enzymatic label or fluorescent label.

Claim 17 (Currently amended): The method of claim 13, wherein the biological sample is selected from the group consisting of tissue, and cells, ~~blood, serum, lymphatic fluid, urine and cerebrospinal fluid.~~

Claims 18-24 (Canceled)

Claims 81-83 (Canceled)